Retroperitoneal sarcomas: combined modality treatment approaches.
Retroperitoneal soft tissue sarcomas are rare tumors estimated to account for 15%of all patients with soft tissue sarcoma seen in referral populations. The standard of care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gross and microscopically negative margins. However, owing to the large size and locally advanced nature of these tumors, this goal is difficult to achieve in most patients. As a result, the disease is characterized by a high propensity for local recurrence and a grade-specific risk for distant metastasis. Over the past decade, there has been considerable research into combined modality treatment of these tumors. The present report outlines current concepts relating to the diagnosis, staging, and management of retroperitoneal sarcomas. Emphasis is placed on evolving combined modality treatment approaches and current investigational strategies.
Pisters
Peter W T
PW
University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. ppisters@mdanderson.org
O'Sullivan
Brian
B
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D007432:Intraoperative Period; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D012509:Sarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*